AU2021237686B2 - Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid - Google Patents

Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid

Info

Publication number
AU2021237686B2
AU2021237686B2 AU2021237686A AU2021237686A AU2021237686B2 AU 2021237686 B2 AU2021237686 B2 AU 2021237686B2 AU 2021237686 A AU2021237686 A AU 2021237686A AU 2021237686 A AU2021237686 A AU 2021237686A AU 2021237686 B2 AU2021237686 B2 AU 2021237686B2
Authority
AU
Australia
Prior art keywords
cocrystal
cyano
thiazol
ylcarbamoyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021237686A
Other languages
English (en)
Other versions
AU2021237686A1 (en
Inventor
Juan CAMACHO GÓMEZ
Julio Castro Palomino Laria
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palobiofarma SL
Original Assignee
Palobiofarma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma SL filed Critical Palobiofarma SL
Publication of AU2021237686A1 publication Critical patent/AU2021237686A1/en
Application granted granted Critical
Publication of AU2021237686B2 publication Critical patent/AU2021237686B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/02—Salts; Complexes; Addition compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2021237686A 2020-03-16 2021-03-15 Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid Active AU2021237686B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382194.7A EP3882240A1 (en) 2020-03-16 2020-03-16 Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid
EP20382194.7 2020-03-16
PCT/EP2021/056506 WO2021185748A1 (en) 2020-03-16 2021-03-15 Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid

Publications (2)

Publication Number Publication Date
AU2021237686A1 AU2021237686A1 (en) 2022-10-06
AU2021237686B2 true AU2021237686B2 (en) 2026-04-09

Family

ID=69953938

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021237686A Active AU2021237686B2 (en) 2020-03-16 2021-03-15 Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid

Country Status (21)

Country Link
US (1) US12384754B2 (cg-RX-API-DMAC10.html)
EP (2) EP3882240A1 (cg-RX-API-DMAC10.html)
JP (1) JP7779846B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220154791A (cg-RX-API-DMAC10.html)
CN (1) CN115298169B (cg-RX-API-DMAC10.html)
AU (1) AU2021237686B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022018449A2 (cg-RX-API-DMAC10.html)
CA (1) CA3171894C (cg-RX-API-DMAC10.html)
DK (1) DK4121419T3 (cg-RX-API-DMAC10.html)
ES (1) ES3002084T3 (cg-RX-API-DMAC10.html)
FI (1) FI4121419T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241515T1 (cg-RX-API-DMAC10.html)
HU (1) HUE068886T2 (cg-RX-API-DMAC10.html)
LT (1) LT4121419T (cg-RX-API-DMAC10.html)
MX (1) MX2022011530A (cg-RX-API-DMAC10.html)
PL (1) PL4121419T3 (cg-RX-API-DMAC10.html)
PT (1) PT4121419T (cg-RX-API-DMAC10.html)
RS (1) RS66214B1 (cg-RX-API-DMAC10.html)
SI (1) SI4121419T1 (cg-RX-API-DMAC10.html)
WO (1) WO2021185748A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202211247B (cg-RX-API-DMAC10.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018162505A1 (en) * 2017-03-06 2018-09-13 Palobiofarma, S.L. Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331220B1 (es) * 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
WO2011158110A2 (en) 2010-04-28 2011-12-22 Nuformix Limited Cilostazol cocrystals and compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018162505A1 (en) * 2017-03-06 2018-09-13 Palobiofarma, S.L. Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid

Also Published As

Publication number Publication date
PT4121419T (pt) 2024-11-18
KR20220154791A (ko) 2022-11-22
EP3882240A1 (en) 2021-09-22
EP4121419B1 (en) 2024-08-14
ES3002084T3 (en) 2025-03-06
HRP20241515T1 (hr) 2025-01-03
HUE068886T2 (hu) 2025-02-28
SI4121419T1 (sl) 2025-02-28
WO2021185748A1 (en) 2021-09-23
LT4121419T (lt) 2024-11-25
RS66214B1 (sr) 2024-12-31
CN115298169B (zh) 2024-11-19
CN115298169A (zh) 2022-11-04
JP7779846B2 (ja) 2025-12-03
US20230183195A1 (en) 2023-06-15
CA3171894A1 (en) 2021-09-23
AU2021237686A1 (en) 2022-10-06
BR112022018449A2 (pt) 2022-11-01
DK4121419T3 (da) 2024-10-28
US12384754B2 (en) 2025-08-12
PL4121419T3 (pl) 2025-02-17
FI4121419T3 (fi) 2024-11-04
CA3171894C (en) 2025-03-11
JP2023517722A (ja) 2023-04-26
MX2022011530A (es) 2022-10-13
ZA202211247B (en) 2023-12-20
EP4121419A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
CN101573350B (zh) 甲磺酸伊马替尼的多晶型及其制备方法以及无定形和α型的甲磺酸伊马替尼
US9365538B2 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2603503B1 (en) Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
ES2562843T3 (es) Forma IV de clorhidrato de ivabradina
JP7237082B2 (ja) 4-(4-(1-イソプロピル-7-オキソ-1,4,6,7-テトラヒドロスピロ[インダゾール-5,4’-ピペリジン]-1’-カルボニル)-6-メトキシピリジン-2-イル)安息香酸の2-アミノ-2-(ヒドロキシメチル)プロパン-1,3-ジオール結晶塩
KR20170061615A (ko) 피마살탄의 신규 염
US20210388027A1 (en) Solid state forms of voclosporin
EP3592734B1 (en) Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid
CA3171894C (en) CARBOXYLIC ACID COCRISTALS (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOLE-2-YLCARBAMOYL)CYCLOPENTANE
EP3652193A1 (en) New crystalline polymorphs of bardoxolone methyl
US10654797B2 (en) Solid forms of an adamantyl compound, compositions and uses thereof
EA045045B1 (ru) Сокристаллы (1r,3s)-3-(5-циано-4-фенил-1,3-тиазол-2-илкарбамоил)циклоопентанкарбоновой кислоты
WO2019134455A1 (zh) Acalabrutinib的新晶型及其制备方法和用途
KR20140022851A (ko) 오타믹사반의 벤조산염
WO2025228973A1 (en) Cocrystals of n-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide
HK40020652B (en) Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl) cyclopentane carboxylic acid
HK40020652A (en) Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl) cyclopentane carboxylic acid
RU2773843C1 (ru) Композиции плинабулина
CN101115706A (zh) 制备普伐他汀钠的方法
CN116847840A (zh) 3,10-二甲氧基-5,8,13,13a-四氢-6H-异喹啉并[3,2-a]异喹啉-9-基3-氟苯磺酸酯及其盐的晶型的多晶型物

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID

FGA Letters patent sealed or granted (standard patent)